



(51) International Patent Classification:

A61B 5/053 (2006.01) A61B 5/00 (2006.01)
A61B 5/04 (2006.01)

(21) International Application Number:

PCT/IL2016/050601

(22) International Filing Date:

9 June 2016 (09.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/173,383 10 June 2015 (10.06.2015) US

(71) Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. [IL/IL]; P.O. Box 12000, 91120 Jerusalem (IL).

(72) Inventor: ROTTENBERG, Yakir; 315 Beit Zecharia St., 9094200 Elazar (IL).

(74) Agents: FISHER, Michal et al.; Webb & Co., P.O. Box 2189, 7612101 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: IMPLANTABLE MONITORING DEVICE




FIG. 1

(57) Abstract: There is provided herein an implantable device for monitoring a condition of a biological tissue, the device comprising: a sensor comprising a plurality of electrodes spaced apart from each other, an electric signal source configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of said plurality of electrodes and an electric signal measurement unit configured to measure impedance values between each of said one or more pairs of electrodes wherein said signals produced by said electric signal measurement unit are indicative of a characteristic of a biological tissue adjacent the pair of electrodes.

IMPLANTABLE MONITORING DEVICE

FIELD OF INVENTION

The present disclosure relates to a medical device for monitoring progression and augmentation of treatment of cancerous tissues. Some embodiments of the invention
5 are directed to therapeutic treatment of solid tumors and causing necrosis of the cancer tissue.

BACKGROUND

Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing with the growth and
10 aging of the population, as well as with the increasing prevalence of carcinogenic risk factors such as smoking, overweight, physical inactivity, and more. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cancer cases and 65% of cancer
15 deaths worldwide. (Torre et al. *CA: A Cancer Journal for Clinicians*, 2015, 65, 87–108). For example, breast cancer is the most common form of malignant disease among women in Western countries and, in the United States, is the most common cause of death among women between 40 and 55 years of age.

Monitoring cancer treatment and progression is challenging and typically
20 requires expensive imaging techniques, such as PET and CT, which are typically employed at intervals of at least 2 months. Usually, these intervals are increased after a few cycles of treatment. There is thus a need for new techniques that would be sufficiently effective, on one hand, and not overly expensive, on the other hand, that would allow monitoring cancer treatment and/or progression.

25 Malignant neoplasms are abnormal tissues that exhibit different characteristics from those of normal tissues. For example, it is known that normal tissues have significantly higher electrical impedance than tumor tissues. Particularly, Morimoto, et al. (*Eur. Surg. Res.* 1990, 22, 86-92) reported measurable differences between impedance values of normal breast tissues, benign breast tumors and malignant breast

tumors. Thus, electrical impedance measurements of body tissues can help distinguish cancerous from healthy tissues, as well as track cancer development or treatment.

For example, Eggers, in U.S. 5,630,426 discloses an apparatus for in situ diagnosis and treatment of tumor tissues, which enables differentiation among normal, malignant tumorous and nonmalignant tumorous biological tissues, by measuring the electrical impedance or the dielectric constant of the tissues. McRae, U.S. Pat. No. 5,069,223, discloses a method in which the electrical impedance of an identified tissue mass is used as a predictive assay of the progress of the hyperthermia treatment. In U.S. 2003/0009110 Tu describes a method of differentiating a tumorous tissue from a normal tissue by measuring the tissue's impedance values over a range of temperatures.

Surgical needles, such as trocar needles, are known and used during surgical procedures to access target body tissue or a target body cavity for observation, treatment, biopsy, and the like. The biopsy operation is a good opportunity to further examine internal physical characteristics of cancerous tissues. Stoianovici, in U.S. 6,337,994 provides a trocar needle, comprising an impedance probe that allows the surgeon to monitor the path of needle insertion, to confirm needle insertion into a desired anatomical target, and/or to identify the nature of cells surrounding the tip of the needle.

Despite the fact that previously described methods and apparatus allow detection and characterization of tissues within a specific time frame (e.g. during the course of a biopsy or another designated operation or imaging), a major deficiency still exists in the field of continuous monitoring of tissues over time.

SUMMARY

The following embodiments and aspects thereof are described and illustrated in conjunction with systems, tools and methods which are meant to be exemplary and illustrative, not limiting in scope.

According to some embodiments, there is provided an implantable device (which may also be referred to as an implant) for monitoring a condition of a biological tissue, the device comprising a sensor comprising a plurality of electrodes spaced apart from

each other, an electric signal source configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of the plurality of electrodes and an electric signal measurement unit configured to measure impedance values between each of the one or more pairs of electrodes wherein the signals produced by
5 the electric signal measurement unit are indicative of a characteristic of the biological tissue adjacent the pair of electrodes.

According to some embodiments, there is provided an implantable device for monitoring a condition of a biological tissue, the device includes a sensor including a plurality of electrodes spaced apart from each other; an electric signal source
10 configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of the plurality of electrodes; an electric signal measurement unit configured to measure impedance values between each of the one or more pairs of electrodes wherein the signals produced by the electric signal measurement unit are indicative of a characteristic of the biological tissue adjacent the pair of electrodes; and
15 an anchoring element configured to anchor the implantable device to the biological tissue or to a neighboring tissue.

According to some embodiments, there is provided a system for monitoring a condition of a biological tissue. The system includes an implantable device for evaluation of a biological tissue and a processing circuitry unit. The device includes: a
20 sensor comprising a plurality of electrodes spaced apart from each other; an electric signal source configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of the plurality of electrodes; an electric signal measurement unit configured to measure impedance values between each of the one or more pairs of electrodes wherein the signals produced by the electric signal
25 measurement unit are indicative of a characteristic of a biological tissue adjacent the pair of electrodes; and an anchoring element configured to anchor the implantable device to the biological tissue or to a neighboring tissue.

According to some embodiments, there is provided a kit for monitoring a condition of a biological tissue. The kit includes an implantable device for evaluation
30 of a biological tissue and a biopsy needle. the device includes: a sensor comprising a plurality of electrodes spaced apart from each other; an electric signal source

configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of the plurality of electrodes; an electric signal measurement unit configured to measure impedance values between each of the one or more pairs of electrodes wherein the signals produced by the electric signal measurement unit are
5 indicative of a characteristic of a biological tissue adjacent the pair of electrodes; and an anchoring element configured to anchor the implantable device to the biological tissue or to a neighboring tissue.

According to some embodiments, there is provided a method for monitoring a condition of a tumor, the method includes: a) using an impedance sensor implanted in
10 the tumor of a subject, providing an electric signal to one or more pairs of neighboring or non-neighboring electrodes of a plurality of electrodes of the sensor; b) measuring, using an electric signal measurement unit, impedance values between each of the one or more pairs of electrodes wherein the signals produced by the electric signal measurement unit are indicative of a characteristic of a biological tissue within or in
15 proximity to the tumor and adjacent the pair of electrodes; c) using a wireless transmitter, wirelessly transmitting the electric signals obtained from the electric signal measurement unit to processing circuitry outside the subject's body; and d) repeating steps a) and b) after a desired period of time, thereby monitoring the condition of the tumor.

20 According to some embodiments, the impedance may be electric impedance.

According to some embodiments, the electrical impedance of the biological tissue may be measured at one or more frequencies in the range of 20 kHz to 20 MHz.

According to some embodiments, the device may further be provided with a power source.

25 According to some embodiments, the device may further include a heating element configured to provide augmentation to a treatment provided to a subject having the tumor.

According to some embodiments, the device may further include a drug releasing component configured to release a drug to the tumor or the tumor's milieu.

According to some embodiments, the wireless transmitter may include a radio transmitter.

According to some embodiments, the wireless transmitter may include a Bluetooth transmitter.

- 5 According to some embodiments, the wireless transmitter may include a wireless passive indicator.

According to some embodiments, the wireless passive indicator may be configured to provide indication to a source outside the body of the subject with the tumor, corresponding to the signals from the electric signal measurement unit.

- 10 According to some embodiments, the wireless passive indicator may include electromechanical systems, such as Piezoelectric, RFID (radio frequency identification) or MEMS (micro-electromechanical systems).

- 15 According to some embodiments, the sensor (or additional sensor/s) may further be configured to measure pH, temperature, dielectric constant, capacitance, certain drug/s (for example, but not limited to, capecitabine) levels within the tumor microenvironment, or any combination thereof.

According to some embodiments, the sensor may further be configured to measure acoustic impedance, biochemical impedance, or both.

According to some embodiments, the biological tissue may include a tumor.

- 20 According to some embodiments, the tumor may be selected from a group consisting of: a solid tumor, a malignant tumor, an adenocarcinoma tumor, an adrenal gland tumor, an ameloblastoma tumor, an anaplastic tumor, an anaplastic carcinoma of the thyroid tumor, an angiofibroma tumor, an angioma tumor, an angiosarcoma tumor, an apudoma tumor, an argentaffinoma tumor, an arrhenoblastoma tumor, an
25 astroblastoma tumor, an astrocytoma tumor, an ataxia-telangiectasia tumor, an atrial myxoma tumor, a basal cell carcinoma tumor, a benign tumor, a bone cancer tumor, a bone tumor, a brainstem glioma tumor, a brain tumor, a breast cancer tumor, a cancerous tumor, a carcinoid tumor, a carcinoma tumor, a cerebellar astrocytoma

tumor, a cervical cancer tumor, a cherry angioma tumor, a cholangiocarcinoma tumor, a cholangioma tumor, a chondroblastoma tumor, a chondroma tumor, a chondrosarcoma tumor, a chorioblastoma tumor, a choriocarcinoma tumor, a colon cancer tumor, , a craniopharyngioma tumor, a cystocarcinoma tumor, a cystofbroma

5 tumor, a cystoma tumor, a cytoma tumor, a ductal carcinoma in situ tumor, a ductal papilloma tumor, a dysgerminoma tumor, an encephaloma tumor, an endometrial carcinoma tumor, an endothelioma tumor, an ependymoma tumor, an epithelioma tumor, an Ewing's sarcoma tumor, a feline sarcoma tumor, a fibro adenoma tumor, a fibro sarcoma tumor, a follicular cancer of the thyroid tumor, a ganglioglioma tumor,

10 a gastrinoma tumor, an aglioblastoma multiform tumor, a glioma tumor, a gonadoblastoma tumor, an haemangioblastoma tumor, an haemangioendothelioblastoma tumor, an haemangioendothelioma tumor, an haemangiopericytoma tumor, an haematolymphangioma tumor, an haemocyto

15 hepatocarcinoma tumor, an hepatocellular carcinoma tumor, an hepatoma tumor, an histoma tumor, a hypernephroma tumor, an infiltrating cancer tumor, an infiltrating ductal carcinoma tumor, an insulinoma tumor, a juvenile angioforoma tumor, a Kaposi sarcoma tumor, a kidney tumor, a lipoma tumor, a liver cancer tumor, a liver metastases tumor, a Lucke carcinoma tumor, a lung cancer tumor, a malignant

20 mesothelioma tumor, a malignant teratoma tumor, a mastocytoma tumor, a medulloblastome tumor, a melanoma tumor, a meningioma tumor, a mesothelioma tumor, a metastatic tumor, a metastasis tumor, a metastatic spread tumor, a Morton's neuroma tumor, a myxoma tumor, a nasopharyngeal carcinoma tumor, a neoplastic tumor, a nephroblastoma tumor, a neuroblastoma tumor, a neurofibroma tumor, a

25 neurofibromatosis tumor, a neuroglioma tumor, a neuroma tumor, an oligodendroglioma tumor, an optic glioma tumor, an osteochondroma tumor, an osteogenic sarcoma tumor, an osteosarcoma tumor, an ovarian cancer tumor, a Paget's disease of the nipple tumor, a pancoast tumor, a pancreatic cancer tumor, a phaeochromocytoma tumor, a pheochromocytoma tumor, a primary brain tumor, a

30 progonoma tumor, a prolactinoma tumor, a renal cell carcinoma tumor, a retinoblastoma tumor, a rhabdomyosarcoma tumor, a rhabdosarcoma tumor, a sarcoma tumor, a secondary tumor, a seminoma tumor, a skin cancer tumor, a small cell carcinoma tumor, a squamous cell carcinoma tumor, a strawberry haemangioma

tumor, a teratoma tumor, a testicular cancer tumor, a thymoma tumor, a trophoblastic tumor, a tumorigenic tumor, a vestibular schwannoma tumor, and a Wilm's tumor. Each possibility represents a separate embodiment of the present disclosure.

5 According to some embodiments, the tumor may be selected from a group of: a solid tumor, a malignant tumor, a benign tumor, a brain tumor, a breast cancer tumor, a cancerous tumor, a carcinoid tumor, a carcinoma tumor, a colon cancer tumor, a cystoma tumor, a kidney tumor, a liver cancer tumor, a lung cancer tumor, a melanoma tumor, a metastatic tumor, a sarcoma tumor, a secondary tumor, a skin cancer tumor.

10 According to some embodiments, the sensor may be configured to be incorporated into a needle.

According to some embodiments, the needle may be selected from the group consisting of a biopsy needle and a trocar needle.

15 According to some embodiments, the processing circuitry unit may further include a user interface for providing an indication of at least one characteristic of the biological tissue.

According to some embodiments, the user interface may include a visual display monitor.

20 According to some embodiments, the visual display monitor may be adapted to displaying the at least one characteristic of the biological tissue in a manner adapted for evaluating the biological tissue by an operator.

According to some embodiments, the processing circuitry unit may further include an indication module configured to provide indication regarding an effectiveness of a treatment provided to the subject implanted with the implantable device.

25 According to some embodiments, the processing circuitry unit may further include a recommendation module configured to provide a recommendation regarding further treatment.

According to some embodiments, the method may include repeating steps a), b) and c) after a desired period of time.

According to some embodiments, the method may further include implanting the sensor essentially within the tumor.

5 According to some embodiments, the implantation may be performed during biopsy.

According to some embodiments, the method may further include providing treatment to the subject, wherein the treatment is intended to affect the tumor, and wherein steps a) and b) are performed at least once after the commencement of the
10 treatment.

According to some embodiments, the desired period of time may be in a range of about 1 to 7 days.

According to some embodiments, the desired period of time may be in a range of about 7-90 days.

15 According to some embodiments, the method may further include augmenting treatment of the tumor using a heating element in or in conjugation with the sensor.

According to some embodiments, the heating may include local heating.

According to some embodiments the local heating may include elevating the temperature of regions of the biological tissue to a range of 40° C to 90° C (for
20 example 60° C to 80° C).

According to some embodiments, the treatment augmentation may include causing necrosis of the tumor.

According to some embodiments, monitoring the condition of the tumor may include an on-line monitoring.

25 According to some embodiments, monitoring the condition of the tumor may include a continuous monitoring.

According to some embodiments, monitoring the condition of the tumor may include monitoring of the effectiveness of a treatment of the tumor.

According to some embodiments, the method may further include displaying the at least one characteristic of the tumor in a manner adapted for evaluating the tumor
5 condition by an operator.

According to some embodiments, the method may include providing indication regarding an effectiveness of a treatment provided to the subject.

According to some embodiments, the method may further include providing a recommendation regarding further treatment.

10 According to some embodiments, the plurality of electrodes may include at least 2 electrodes.

According to some embodiments, the plurality of electrodes may include at least 3 electrodes.

15 According to some embodiments, the plurality of electrodes may include at least 5 electrodes.

According to some embodiments, the plurality of electrodes may include at least 10 electrodes.

According to some embodiments, the plurality of electrodes may include at least 20 electrodes.

20 According to some embodiments, the plurality of electrodes may include at least 50 electrodes.

According to some embodiments, the plurality of electrodes may include at least 100 electrodes.

25 According to some embodiments, the plurality of electrodes may include a two-dimensional, matrix-like array of electrodes.

According to some embodiments, the implantable device may further include an anchoring element, configured for fixing the device in or adjacent to the biological tissue, which is to be monitored during the monitoring period. The anchoring element is configured to prevent the dislocation of the implantable device during the
5 monitoring period. According to some embodiments, the anchoring element may further be fastened and/or secured to the biological tissue during or after the implantation.

According to some embodiments, the anchoring element may include hooks and or spikes. According to some embodiments, the anchoring element may be deployed
10 after the device was removed from the biopsy needle or from any other applicator.

According to some embodiments, the anchoring element may include an adhesive material. According to some embodiments, the fixing, fastening and/or securing may be performed by activating the adhesive material, for example by heat, radiation and/or by inducing any type of curing. According to some embodiments, the
15 anchoring element may include a suture, a string, a wire and/or a thread, and the fixing, fastening and/or securing may be performed by suturing and/or tying the device to the region of interest, such as the tumor or a neighboring tissue. According to some embodiments, the anchoring element may include a clip, and the fixing, fastening and/or securing of the anchoring element may be performed by applying force and/or
20 torsion, thus connecting the implant to the region of interest, such as the tumor or a neighboring tissue.

According to some embodiments, the anchoring element is configured to anchor the implantable device to a tissue, which is a neighboring tissue to the biological tissue to be monitored. According to some embodiments, the neighboring tissue is a tissue or
25 an organ in proximity to the biological tissue to be monitored. According to some embodiments, the neighboring tissue may be a bone (for example, but not limited to, a skull bone, a rib, the sternum, a vertebra, or any other bone) or a connective tissue (for example, cartilage) in proximity to the biological tissue to be monitored.

According to some embodiments, the provided implantable device is configured
30 to continuously monitor a condition of a biological tissue over time (for example,

during hours, days, weeks or months), thus providing more meaningful data than a device which enables differentiation of normal tissues compared to cancerous tissues in a single point of time or during a certain procedure such as a biopsy.

According to some embodiments, the provided implantable device (or any processor related thereto) may be configured to provide integral analyses of a plurality of variables (for example, but not limited to, tumor type, specific drug, time from beginning of treatment and subject's age, gender and/or medical history) and the final result and/or output of the continuous monitoring may include a continuous variable of response (such as, but not limited to, 'excellent', 'good', 'improved comparing to a previous time point', etc.), rather than a dichotomic response (e.g. yes/ no).

According to some embodiments, the implantable device may further provide information with a spatial resolution. In other words, the device may be configured to discriminate (differentiate) between a homogenous response to treatment and a heterogeneous response within the biological tissue. For example, the device may provide indication of necrosis at a specific region of the biological tissue (for example, at the center of a tumor), while indicating no or reduced effect on other regions of the biological tissue (for example, in peripheral areas of the tumor). According to some embodiments, such regional discrimination may also differentiate between sub-populations of cancer cells with distinctive features, such as, but not limited to, aggressiveness and/or responsiveness to certain treatment. In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed description.

BRIEF DESCRIPTION OF THE FIGURES

Exemplary embodiments are illustrated in referenced figures. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown to scale. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive. The figures are listed below.

Fig. 1 schematically shows a biopsy assembly including a syringe and an implantable impedance sensing device inserted into the needle, according to some embodiments;

5 Figs. 2a and 2b schematically show a subject having a breast tumor before implantation of an implantable impedance sensor (Fig. 2a) and after implantation of an implantable impedance sensor (Fig 2b), according to some embodiments;

Fig. 3 schematically shows a block diagram of an implantable impedance sensing device, according to some embodiments;

10 Fig. 4 schematically shows a block diagram of an implantable impedance sensing device, according to some embodiments;

Fig. 5 schematically shows a block diagram of an impedance monitoring system, according to some embodiments;

Fig. 6 schematically shows a flow chart of a method for monitoring a condition of a tumor; and

15 Figs. 7a – 7g schematically show impedance values of tumors implanted with implantable impedance sensing devices vs. time, according to some embodiments.

DETAILED DESCRIPTION

20 The following description relates to one or more non-limiting examples of embodiments of the invention. The invention is not limited by the described embodiments or drawings, and may be practiced in various manners or configurations or variations. The terminology used herein should not be understood as limiting unless otherwise specified.

The non-limiting section headings used herein are intended for convenience only and should not be construed as limiting the scope of the invention.

25 Reference is made to Fig. 1, which schematically shows a biopsy assembly **200** including a syringe **202** having a needle **204** and an implantable impedance sensing device **206** inserted into needle **204**, according to some embodiments.

Implantable impedance sensing device **206** is configured to fit inside a lumen of biopsy needle **204**. Implantable impedance sensor **206** is also shown, in needle **204**, in an enlarged view **208**. Implantable impedance sensing device **206** includes a plurality of isolated electrodes **210** and is configured to provide an electric signal corresponding to the electrical impedance between any pair of two electrodes of plurality of isolated electrodes **210**.

Reference is made to Figs. 2a and 2b, which schematically show a subject having a breast tumor before implantation of an implantable impedance sensing device (Fig. 2a) and after implantation of an implantable impedance sensing device (Fig. 2b), according to some embodiments;

Fig. 2a represents a female subject **400** suffering from breast cancer, with a solid tumor **402** located inside her top right breast. Fig. 2b represents female subject **400**, with solid tumor **402** located inside her top right breast after implantation of an implantable impedance sensing device **404**. After implantation, implantable impedance sensing device **404** is located substantially in the center of solid tumor **402**. According to some embodiments, implantable impedance sensing device **404** is configured to fit inside and be contained within solid tumor **402**, as shown in Fig. 2b. It is noted that according to some embodiments, implantable impedance sensing device **404** may be only partially located within a tumor. As detailed herein, implantable impedance sensing device **404** is configured to provide signals corresponding to impedance, which provide indication relating to the tumor progression, remission and/or reaction to treatment.

Reference is made to Fig. 3, which schematically shows a block diagram of an implantable impedance sensing device **500**, according to some embodiments. According to some embodiments, implantable impedance sensing device **500** comprises a plurality of isolated electrodes **502** spaced apart from each other, which are logically connected to a single electric signal source **506** and to a single electric signal measurement unit **508** via a selection switch **504**. It should be noted that the total number of electrodes may be any odd or even number higher than one (for example, 2-8, 3-10, 5-15, 10-100, 10-500 etc.), and not limited to a specific number as in the examples. It is also noted that plurality of isolated electrodes **502** may include a

two-dimensional electrode, matrix-like array, in which each electrode is spaced apart from others.

Implantable impedance sensing device **500** is configured to provide an electric signal corresponding to the electrical impedance between any pair of two electrodes of plurality of isolated electrodes **502**. According to some embodiments, to avoid stray capacitances, the electrodes may be connected via shielded wires to selection switch **504**, which may select a specific pair of neighboring or non-neighboring electrodes, following a command from electric signal source **506**. In order for implantable impedance sensing device **500** to provide an electric signal corresponding to the electrical impedance between a pair of two electrodes of plurality of isolated electrodes **502**, electric signal measurement unit **508** is provided for measuring impedance values between a selected pair of electrodes of plurality of isolated electrodes **502**. According to some embodiments, the signals are produced by electric signal measurement unit **508**.

According to some embodiments, for the sake of allowing optimal monitoring of the tissue (such as tumor) condition, in which implantable impedance sensing device **500** is implanted, from outside subject body, a wireless indicator **510** is provided and configured to receive signal data from electric signal measurement unit **508** and from electric signal source **506**. Wireless indicator **510** is further configured to provide wireless indication to a source outside the body, corresponding to the received signal data from electric signal measurement unit **508** and from electric signal source **506**. According to some embodiments, wireless indicator **510** may be an active indicator, such as, but not limited to, a wireless transmitter configured to transmit signals in radio frequency as a wireless indication, for example, but not limited to, Bluetooth communication. According to some embodiments, wireless indicator **510** may be a passive indicator, which provides a passive physical indication, which can be detected from outside the body, by an appropriate apparatus, thus providing a wireless indication. Such passive indicators may include electromechanical systems, such as Piezoelectric, RFID (radio frequency identification) or MEMS (micro-electromechanical systems).

Reference is made to Fig. 4, which schematically shows a block diagram of an implantable impedance sensing device **600**, according to some embodiments. According to some embodiments, implantable impedance sensing device **600** comprises a plurality of isolated electrodes **601-604** spaced apart from each other, and
5 each pair of electrodes of plurality of isolated electrodes **601-604** is logically connected to a single electric signal source of electric signal sources **611-616** and to a single electric signal measurement unit of electric signal measurement units **621-626**. It should be noted that the total number of electrodes may be any odd or even number higher than one (for example, 2-8, 3-10, 5-15, 10-100, 10-500 etc.), and not limited to
10 a specific number as in the examples.

Implantable impedance sensing device **600** is configured to provide an electric signal corresponding to the electrical impedance between any pair of two electrodes of plurality of isolated electrodes **601-604**. Electric signal sources **611-616** may supply electric current or voltage to the pair of electrodes of plurality of isolated electrodes
15 **601-604**, to which it is logically connected. In order for implantable impedance sensing device **600** to provide an electric signal corresponding to the electrical impedance between a pair of two electrodes of plurality of isolated electrodes **601-604**, each one of electric signal measurement units **621-626** is configured to implantable impedance sensing device **600** for measuring impedance values between the pair of
20 electrodes of plurality of isolated electrodes **601-604**, to which it is logically connected. According to some embodiments, the signals are produced by electric signal measurement units **621-626**.

According to some embodiments, for the sake of allowing optimal monitoring of the tissue (such as tumor) condition, in which implantable impedance sensing device
25 **600** is implanted, from outside subject body a wireless indicator **610** is provided and configured to receive signal data from each one of electric signal measurement units **621-626** and from each one of electric signal sources **611-616**. Wireless indicator **610** is further configured to provide wireless indication to a source outside the body, corresponding to the received signal data from each one of electric signal measurement
30 units **621-626** and from each one of electric signal sources **611-616**. According to some embodiments, wireless indicator **610** may be an active indicator, such as, but not limited to, a wireless transmitter configured to transmit signals in radio frequency as a

wireless indication, for example, but not limited to, Bluetooth communication. According to some embodiments, wireless indicator **610** may be a passive indicator, which provides a passive physical indication, which can be detected from outside the body, by an appropriate apparatus, thus providing a wireless indication. Such passive
 5 indicators may include electromechanical systems, such as Piezoelectric, RFID (radio frequency identification) or MEMS (micro-electromechanical systems).

In an alternative configuration, also presented in Fig. 4, according to some embodiments, implantable impedance sensing device **600** includes a plurality of isolated electrodes **601-604** spaced apart from each other, and one electrode is selected
 10 as a reference electrode. It should be noted that the total number of electrodes may be any odd or even number higher than one (for example, 2-8, 3-10, 5-15, 10-100, 10-500 etc.), and not limited to a specific number as in the examples. For the sake of illustration in Fig. 4, isolated electrode **601** is selected as the reference electrode. Each isolated electrode, not selected as the reference electrode (isolated electrodes **602-604**
 15 in the example in Fig. 4) forms a primary pair together with the reference electrode (in the example in Fig. 4, the primary pair are formed from isolated electrodes; **601** and **602**; **601** and **603**; and **601** and **604**). Electrode pairs which are not defined as primary pairs are defined as secondary pairs. For example, in the example of Fig. 4, secondary pairs are formed from isolated electrodes: **602** and **603**; **602** and **604**; and **603** and **604**.
 20 Each primary pair is logically connected to a single electric signal source of electric signal sources **611-613** and to a single electric signal measurement unit of electric signal measurement units **621-623**. In this alternative configuration, electric signal sources **614-616** and electric signal measurement units **624-626** in Fig. 4 may be absent. It should be noted that the total number of electric signal measurement units
 25 and electric signal sources may be any odd or even positive number (for example, 2-8, 3-10, 5-15, 10-100, 10-500 etc.), and not limited to a specific number as in the examples.

Also in the alternative configuration, implantable impedance sensing device **600** is configured to provide an electric signal corresponding to the electrical impedance
 30 between any pair of two electrodes of plurality of isolated electrodes **601-604**, including both primary and secondary pairs. Electric signal sources **611-613** may supply electric current or voltage to the primary pairs of electrodes of plurality of

isolated electrodes **601-604**, to which it is logically connected. In order for implantable impedance sensing device **600** to provide an electric signal corresponding to the electrical impedance between a primary pair of two electrodes of plurality of isolated electrodes **601-604**, each one of electric signal measurement units **621-623** is

5 configured to implantable impedance sensing device **600** for measuring impedance values between the primary pair of electrodes of plurality of isolated electrodes **601-604**, to which it is logically connected. According to some embodiments, the signals are produced by electric signal measurement units **621-623**. Implantable impedance sensing device **600** may also provide an electric signal corresponding to the electrical

10 impedance between a secondary pair of two electrodes of plurality of isolated electrodes **602-604**. The impedance values between secondary pairs of electrodes of plurality of isolated electrodes **602-604** are calculated based on impedance values between the primary pair of electrodes of plurality of isolated electrodes **601-604**. For example, in the alternative configuration of Fig. 4, the impedance values between

15 isolated electrode **602** and isolated electrode **603** is calculated based on the impedance values between isolated electrode **601** and isolated electrode **602** and on the impedance values between isolated electrode **601** and isolated electrode **603**. According to some embodiments of the alternative configuration, for the sake of allowing optimal monitoring of the tissue (such as tumor) condition, in which implantable impedance

20 sensing device **600** is implanted, from outside subject body, a wireless indicator **610** is provided and configured to receive signal data from each one of electric signal measurement units **621-623** and from each one of electric signal sources **611-613**. Wireless indicator **610** is further configured to provide wireless indication to a source outside the body, corresponding to the received signal data from each one of electric

25 signal measurement units **621-623** and from each one of electric signal sources **611-613**. According to some embodiments, wireless indicator **610** may be an active indicator, such as, but not limited to, a wireless transmitter configured to transmit signals in radio frequency as a wireless indication, for example, but not limited to, Bluetooth communication. According to some embodiments, wireless indicator **610**

30 may be a passive indicator, which provides a passive physical indication, which can be detected from outside the body, by an appropriate apparatus, thus providing a wireless indication. Such passive indicators may include electromechanical systems, such as

Piezoelectric, RFID (radio frequency identification) or MEMS (micro-electromechanical systems).

Implantable impedance sensing devices **500** (Fig. 3) or **600** (Fig. 4) may be used, for example, according to an impedance monitoring method, as part of an impedance monitoring system or an impedance monitoring kit, as described herein. Implantable impedance sensing devices **500/600** may be used *in-vivo*, for example, in conjunction with treating a patient; or may be used *ex-vivo*; or may be used externally to a human body, or without any relation to treating the human body. Optionally, the method, corresponding to implantable impedance sensing devices **500/600** may include calibrating implantable impedance sensing devices **500/600**, or otherwise establishing baseline measurement value(s).

Reference is made to Fig. 5, which schematically shows a block diagram of an impedance monitoring system **700**, according to some embodiments. According to some embodiments, impedance monitoring system **700** includes an implantable impedance sensing device **750**, which includes a wireless indicator **710**. According to some embodiments, wireless indicator **710** is configured to receive signal data indicative of a characteristic of a biological tissue (such as a tumor) into which implantable impedance sensing device **750** is implanted. According to some embodiments, wireless indicator **710** is further configured to provide wireless indication to a source outside the body, corresponding to the characteristic of a biological tissue into which implantable impedance sensing device **750** is implanted. According to some embodiments, wireless indicator **710** may be an active indicator, such as, but not limited to, a wireless transmitter configured to transmit signals in radio frequency as a wireless indication, for example, but not limited to, Bluetooth communication. According to some embodiments, wireless indicator **710** may be a passive indicator, which provides a passive physical indication, which can be detected from outside the body, by an appropriate apparatus, thus providing a wireless indication. Such passive indicators may include electromechanical systems, such as Piezoelectric, RFID (radio frequency identification) or MEMS (micro-electromechanical systems).

Fig. 5 depicts a case in which an active wireless transmitter is used as wireless indicator **710**. It is configured to wirelessly transmit electric signals to a processing circuitry unit **712** corresponding to at least one characteristic of a biological tissue into which implantable impedance sensing device **750** is implanted. According to some
5 embodiments, the characteristic is electrical impedance.

According to some embodiments, processing circuitry unit **712** may be configured to wirelessly receive and analyze signals obtained from wireless indicator **710**. According to some embodiments, wireless indicator **710** is a wireless transmitter, and processing circuitry unit **712** is configured to periodically and regularly establish a
10 wireless communication channel with wireless indicator **710** within an established communication channel. According to some embodiments, processing circuitry unit **712** is configured to periodically generate data values corresponding to the wireless signals received from wireless indicator **710** and indicative of at least one characteristic of a biological tissue into which implantable impedance sensing device
15 **750** is implanted. Optionally, processing circuitry unit **712** operates in conjunction with a user interface, comprising a visual display monitor, **714**, which is adapted to displaying impedance measurements of implantable impedance sensing device **750**, in a manner adapted for evaluating the biological tissue by an operator.

According to some embodiments, a machine-learning algorithm is utilized for the
20 monitoring of a condition of a tumor. According to some embodiments, the algorithm is configured to provide predictions for the diagnostic result in each case, the predictions having a probability of correctness factor. The prediction of the learning machine is then checked for correctness, and the algorithm is directed accordingly. In case the prediction turns out to be correct, the algorithm reinforces its calculation,
25 thereby increasing the probability of the same prediction in similar future cases. In case the prediction turns out to be incorrect, the algorithm corrects its calculation, thereby decreasing the probability of the same prediction in similar future cases. The enforcement and correction mechanism described above may enable the algorithm to “learn” the behavior of cancerous tumors and provide a predicted diagnosis with high
30 accuracy. According to some embodiments, the enforcement and correction mechanism is directed by a person (medical professional and/or computer professional). According to some embodiments, the enforcement and correction

mechanism is directed by another algorithm, machine, computer, cloud, or the like, and/or any combination thereof. According to some embodiments, such an algorithm may include predetermined basic heuristics for detection of cancerous tumors and/or monitoring a condition of a tumor, for example, monitoring progression and/or augmentation of treatment of cancerous tissues. According to some embodiments, a pattern recognition algorithm is utilized. According to some embodiments, a computational learning algorithm is utilized. According to some embodiments, an artificial intelligence algorithm is utilized. According to some embodiments, one or more of the algorithms may be executed by the processing circuitry. According to some embodiments, one or more of the algorithms may be executed by an independent, remote and/or external processing circuitry, such as a remote server, a cloud server, a local computer and others.

Impedance monitoring system **700** may be used, for example, in conjunction with an impedance monitoring method or an impedance monitoring kit as described herein. The system may be used *in-vivo*, or in conjunction with treating a patient; or may be used *ex-vivo*; or may be used externally to a human body, or without any relation to treating the human body. Optionally, the method, corresponding to the impedance monitoring system, may include calibrating implantable impedance sensing device **750**, or otherwise establishing baseline measurement value(s). The method may further include implanting implantable impedance sensing device **750** into a tissue in a human subject's body. According to some embodiments, the tissue is a tumor tissue, and according to some embodiments, the implantation is performed during biopsy.

Reference is made to Fig. 6, which schematically shows a flow chart of a method for monitoring a condition of a tumor, **760**, according to some embodiments. According to some embodiments, method **760** includes the following steps:

Step **762** - providing an electric signal to one or more pairs of electrodes of a sensor implanted in a tumor. According to some embodiments, step **762** may be done using an impedance sensor. According to some embodiments, the one or more pairs of electrodes are one or more pairs of neighboring or non-neighboring electrodes of a plurality of electrodes of the sensor.

Step **764** - measuring impedance values between the pairs of electrodes, thus producing signals indicative of a characteristic of a biological tissue within or in proximity to the tumor and adjacent the pair of electrodes. According to some embodiments, the measurements may be performed using an electric signal measurement unit. According to some embodiments, the electric signal measurement unit is producing the signals indicative of a characteristic of a biological tissue within or in proximity to the tumor and adjacent the pair of electrodes. According to some embodiments, the impedance values are measured between each of one or more pairs of electrodes of a plurality of electrodes.

Step **766** - wirelessly transmitting the obtained signals to processing circuitry. According to some embodiments, the transmitting is performed using a wireless transmitter. According to some embodiments, the obtained signals are electric signals obtained from the electric signal measurement unit. According to some embodiments, the processing circuitry is located outside the subject's body.

According to some embodiments, steps **762** and **764** are repeated after a desired period of time thereby monitoring the condition of the tumor. According to some embodiments, steps **762**, **764** and **766** are repeated after a desired period of time, thereby monitoring the condition of the tumor.

Reference is made to Figs 7a – 7g, which schematically show impedance values around regions of tumors implanted with implantable impedance sensing devices **850** vs. time, according to some embodiments.

Without being bound by any theory or mechanism, normal tissues have higher (typically significantly higher) electrical impedance than tumor tissues, which can help monitoring cancer development or effects of treatment on the tumor. Consequently, a successful treatment of a tumor (such as malignant neoplasm), resulting in at least a partial necrosis or reduction in volume of the abnormal tissue, would also result in an increase of electrical impedance measured inside that tissue. Moreover, success of the treatment should be inversely proportional to the measured impedance.

For example, Fig. 7a shows an illustrative representation of measured tumor impedance vs. time, in a successful treatment, resulting in a moderate attenuation of

the tumor size. At the beginning of the treatment, $t = t_0$, the tumor is a large tumor, **860**, depicted as a large ellipsoid, wholly containing an implantable impedance sensing device **850**. Reference is made to time-point $t = t_1$, which may represent any point of time in the duration or completion of the treatment, later than $t = t_0$. At $t = t_1$ the tumor, which represents the same tumor in $t = t_0$, is now a medium tumor, **870** depicted as a medium ellipsoid, still wholly containing implantable impedance sensing device **850**. According to the illustration depicted in Fig. 7a, the measured impedance is gradually increasing with time, and with tumor volume reduction due to the action of the successful treatment. Additionally, the moderate slope of the graph in Fig. 7a indicates a moderate decrease in tumor size between $t = t_0$ and $t = t_1$ corresponding to the moderate decrease in tumor size.

Fig. 7b is an illustrative representation of measured tumor impedance vs. time, in a successful treatment, resulting in a substantial attenuation of the tumor size. At the beginning of the treatment, $t = t_0$, the tumor is a large tumor, **861**, as in Fig. 7a, $t=t_0$. Reference is made to time-point $t = t_1$, which may represent any point of time in the duration or completion of the treatment, later than $t = t_0$. At $t = t_1$ the tumor, which represents the same tumor in $t = t_0$, is now a small tumor, **881** depicted as a small ellipsoid, not large enough to contain implantable impedance sensing device **850**. According to the illustration depicted in Fig. 7b, the measured impedance is gradually increasing with time, and with tumor volume reduction due to the action of the successful treatment. Additionally, the slope of the graph in Fig. 7b is steeper than the corresponding slope in Fig. 7a, indicating a more substantial decrease in tumor size between $t = t_0$ and $t = t_1$ in the case depicted in Fig. 7b than in the decrease in tumor size between $t = t_0$ and $t = t_1$ in the case depicted in Fig. 7a.

Fig. 7c is an illustrative representation of measured tumor impedance vs. time, in a successful treatment, resulting in a very significant reduction of the tumor size. At the beginning of the treatment, $t = t_0$, the tumor is a large tumor, **862** as in Figs. 7a and 7b ($t = t_0$). Reference is made to time-point $t = t_1$, which may represent any point of time in the duration or completion of the treatment, later than $t = t_0$. At $t = t_1$ the tumor, which represents the same tumor in $t = t_0$, is now a very small tumor, **892** depicted as a very small ellipsoid, not large enough to contain implantable impedance sensing device **850**. According to the illustration depicted in Fig. 7c, the measured

impedance is gradually increasing with time, and with tumor volume reduction due to the action of the successful treatment. Additionally, the slope of the graph in Fig. 7c is steeper than the corresponding slopes in Figs. 7a and 7b, indicating a more significant decrease in tumor size between $t = t_0$ and $t = t_1$ in the case depicted in Fig. 7c than in the decreases in tumor sizes between $t = t_0$ and $t = t_1$ in the cases depicted in Figs. 7a and 7b.

Reference is made to Fig. 7d, which is an illustrative representation of measured tumor impedance vs. time, in a non-successful treatment, not resulting in visible change of tumor size. At the beginning of the treatment, $t = t_0$, the tumor is a medium tumor, **873** as in Fig. 7a, $t = t_1$. No visible change in tumor size is witnessed at time-point $t = t_1$, which may represent any point of time in the duration or completion of the treatment, later than $t = t_0$, and the tumor is still a medium tumor, **872**. According to the illustration depicted in Fig. 7d, the measured impedance is practically constant with time, indicating an unchanged tumor volume between $t = t_0$ and $t = t_1$.

Fig. 7e is an illustrative representation of measured tumor impedance vs. time, in another unsuccessful treatment, resulting in an enlargement of the tumor size. At the beginning of the treatment, $t = t_0$, the tumor is a medium tumor, **874** as in Fig. 7a, $t = t_1$. Reference is made to time-point $t = t_1$, which may represent any point of time in the duration or completion of the treatment, later than $t = t_0$. At $t = t_1$ the tumor, which represents the same tumor in $t = t_0$, is now a large tumor, **864**, as in Fig. 7a, $t = t_0$. According to the illustration depicted in Fig. 7e, the measured impedance is gradually decreasing with time, and with tumor enlargement. Additionally, the moderate slope of the graph in Fig. 7e indicative of a moderate increase in tumor size between $t = t_0$ and $t = t_1$.

Reference is made to Figs. 7f and 7g, which are illustrative representations of measured tumor impedances vs. time, in successful treatments, resulting in necroses of the abnormal tissues. At the beginning of the treatments, $t = t_0$, the tumors are non-necrotic large tumors, **865** (Fig. 7f, $t = t_0$) and **845** (Fig. 7g, $t = t_0$). Reference is made to time-points $t = t_1$ in Figs. 7f and 7g, which may represent any points of time in the durations or completions of the treatments, later than $t = t_0$ in Figs. 7f and 7g. At $t = t_1$ the tumors in Figs. 7f and 7g, which represent the same tumors in $t = t_0$ in Figs. 7f and

7g, are now necrotic tumors, **866** (Fig. 7f, $t = t_1$) and **846** (Fig. 7g, $t = t_1$), still wholly containing implantable impedance sensing devices **850**. According to the illustration depicted in Fig. 7f and 7g, the measured impedances are gradually increasing with time, and with the tumors' necroses due to the actions of the successful treatments.

5 While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced be interpreted to include all such modifications, permutations, additions and sub-combinations as are within their true
10 spirit and scope.

 Data may be analyzed by using a local or remote processing unit, processor, controller, Integrated Circuit (IC), system on a chip (SOC), workstation, portable electronic device, smartphone, tablet, laptop, general-purpose computing device, or other suitable device. Optionally, data processing may be performed live or in real-
15 time by a server which may provide processing services to multiple or many units, based on a subscription fee, a pay-per-use fee, a pay-per-time-period subscription fee, or other suitable methods.

 Some embodiments of the present disclosure may be implemented by utilizing any suitable combination of hardware components and/or software modules; as well as
20 other suitable units or sub-units, processors, controllers, DSPs, CPUs, Integrated Circuits, output units, input units, memory units, long-term or short-term storage units, buffers, power source(s), wired links, wireless communication links, transceivers, Operating System(s), software applications, drivers, or the like.

 In the description and claims of the application, each of the words “comprise”
25 “include” and “have”, and forms thereof, are not necessarily limited to members in a list with which the words may be associated.

CLAIMS

What is claimed is:

1. An implantable device for monitoring a condition of a biological tissue,
the device comprising:
 - 5 a sensor comprising a plurality of electrodes spaced apart from each other;

an electric signal source configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of said plurality of electrodes;
 - 10 an electric signal measurement unit configured to measure impedance values between each of said one or more pairs of electrodes wherein said signals produced by said electric signal measurement unit are indicative of a characteristic of the biological tissue adjacent the pair of electrodes; and
 - 15 an anchoring element configured to anchor the implantable device to the biological tissue or to a neighboring tissue.
2. The device according to claim 1, further comprising a wireless transmitter configured to wirelessly transmit said electric signals obtained from said electric signal measurement unit.
- 20 3. The device according to claim 1, wherein said impedance is electric impedance.
4. The device according to claim 1, further comprising a power source.
5. The device according to claim 1, further comprising a heating element configured to provide augmentation to a treatment provided to a subject
25 having the tumor.

6. The device according to claim 1, further comprising a drug releasing component configured to release a drug to the tumor or the tumor's milieu.
- 5 7. The device according to claim 2, wherein said wireless transmitter comprises a radio transmitter.
8. The device according to claim 2, wherein said wireless transmitter comprises a Bluetooth transmitter.
9. The device according to claim 1, wherein said sensor is further configured to measure pH, temperature, dielectric constant, capacitance or any combination thereof.
- 10 10. The device according to claim 1, wherein said sensor is further configured to measure acoustic impedance, biochemical impedance, or both.
11. The device according to claim 1, wherein said biological tissue comprises a tumor.
- 15 12. The device according to claim 11 wherein said tumor comprises a breast cancer tumor.
13. The device according to claim 11, wherein said tumor is selected from a group consisting of: a solid tumor, a malignant tumor, an adenocarcinoma tumor, an adrenal gland tumor, an ameloblastoma tumor, an anaplastic tumor, an anaplastic carcinoma of the thyroid tumor, an angiofibroma tumor, an angioma tumor, an angiosarcoma tumor, an apudoma tumor, an argentaffinoma tumor, an arrhenoblastoma tumor, an astroblastoma tumor, an astrocytoma tumor, an ataxia-telangiectasia tumor, an atrial myxoma tumor, a basal cell carcinoma tumor, a benign tumor, a bone cancer tumor, a bone tumor, a brainstem glioma tumor, a brain tumor, a breast cancer tumor, a cancerous tumor, a carcinoid tumor, a carcinoma tumor, a cerebellar astrocytoma tumor, a cervical cancer tumor, a cherry angioma tumor, a cholangiocarcinoma
- 20
- 25

tumor, a cholangioma tumor, a chondroblastoma tumor, a chondroma tumor, a chondrosarcoma tumor, a chorioblastoma tumor, a choriocarcinoma tumor, a colon cancer tumor, a craniopharyngioma tumor, a cystocarcinoma tumor, a cystofibroma tumor, a cystoma tumor, a cytoma tumor, a ductal carcinoma in situ tumor, a ductal papilloma tumor, a dysgerminoma tumor, an encephaloma tumor, an endometrial carcinoma tumor, an endothelioma tumor, an ependymoma tumor, an epithelioma tumor, an Ewing's sarcoma tumor, a feline sarcoma tumor, a fibro adenoma tumor, a fibro sarcoma tumor, a follicular cancer of the thyroid tumor, a ganglioglioma tumor, a gastrinoma tumor, aglioblastoma multiform tumor, a glioma tumor, a gonadoblastoma tumor, an haemangioblastoma tumor, an haemangioendothelioblastoma tumor, an haemangioendothelioma tumor, an haemangiopericytoma tumor, an haematolymphangioma tumor, an haemocytoblastoma tumor, an haemocytoma tumor, a hamartoma tumor, an hepatocarcinoma tumor, an hepatocellular carcinoma tumor, an hepatoma tumor, an histoma tumor, an hypernephroma tumor, an infiltrating cancer tumor, an infiltrating ductal carcinoma tumor, an insulinoma tumor, a juvenile angioforoma tumor, a Kaposi sarcoma tumor, a kidney tumor, a lipoma tumor, a liver cancer tumor, a liver metastases tumor, a Lucke carcinoma tumor, a lung cancer tumor, a malignant mesothelioma tumor, a malignant teratoma tumor, a mastocytoma tumor, a medulloblastome tumor, a melanoma tumor, a meningioma tumor, a mesothelioma tumor, a metastatic tumor, a metastasis tumor, a metastatic spread tumor, a Morton's neuroma tumor, a myxoma tumor, a nasopharyngeal carcinoma tumor, a neoplastic tumor, a nephroblastoma tumor, a neuroblastoma tumor, a neurofibroma tumor, a neurofibromatosis tumor, a neuroglioma tumor, a neuroma tumor, an oligodendroglioma tumor, an optic glioma tumor, an osteochondroma tumor, an osteogenic sarcoma tumor, an osteosarcoma tumor, an ovarian cancer tumor, a Paget's disease of the nipple tumor, a pancoast tumor, a pancreatic cancer tumor, a phaeochromocytoma tumor, a pheoehromocytoma tumor, a primary brain tumor, a progonoma tumor, a prolactinoma tumor, a renal cell

- 5 carcinoma tumor, a retinoblastoma tumor, a rhabdomyosarcoma tumor, a rhabdosarcoma tumor, sarcoma tumor, a secondary tumor, a seminoma tumor, a skin cancer tumor, a small cell carcinoma tumor, a squamous cell carcinoma tumor, a strawberry haemangioma tumor, a teratoma tumor, a testicular cancer tumor, a thymoma tumor, a trophoblastic tumor, a tumorigenic tumor, a vestibular schwannoma tumor, and a Wilm's tumor.
- 10 14. The device according to claim 11, wherein said tumor is selected from a group consisting of: a solid tumor, a malignant tumor, a benign tumor, a brain tumor, a breast cancer tumor, a cancerous tumor, a carcinoid tumor, a carcinoma tumor, a colon cancer tumor, a cystoma tumor, a kidney tumor, a liver cancer tumor, a lung cancer tumor, a melanoma tumor, a metastatic tumor, sarcoma tumor, a secondary tumor, a skin cancer tumor.
- 15 15. The device according to claim 1, wherein said sensor is configured to be incorporated into a needle.
16. The device according to claim 15, wherein said needle is selected from the group consisting of a biopsy needle and a trocar needle.
- 20 17. A system for monitoring a condition of a biological tissue, the system comprising:
- an implantable device for evaluation of a biological tissue, the device comprising:
- 25 a sensor comprising a plurality of electrodes spaced apart from each other;
- an electric signal source configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of said plurality of electrodes;

an electric signal measurement unit configured to measure impedance values between each of said one or more pairs of electrodes wherein said signals produced by said electric signal measurement unit are indicative of a characteristic of a biological tissue adjacent the pair of electrodes; and

an anchoring element configured to anchor the implantable device to the biological tissue or to a neighboring tissue; and

a processing circuitry unit configured to receive and analyze said electric signals obtained from said transmitter.

18. The system according to claim 17, wherein the implantable device further comprises a wireless transmitter configured to wirelessly transmit said electric signals obtained from said electric signal measurement unit; and wherein the processing circuitry unit is configured to wirelessly receive and analyze said electric signals obtained from said transmitter.

19. The system according to claim 17, wherein said processing circuitry unit further comprises a user interface for providing an indication of at least one characteristic of said biological tissue.

20. The system according to claim 19, wherein said user interface comprises a visual display monitor.

21. The system according to claim 20, wherein said visual display monitor is adapted to displaying said at least one characteristic of said biological tissue in a manner adapted for evaluating the biological tissue by an operator.

22. The system according to claim 17, wherein said processing circuitry unit further comprises an indication module configured to provide indication regarding an effectiveness of a treatment provided to the subject implanted with said implantable device.

23. The system according to claim 17, wherein said processing circuitry unit further comprises a recommendation module configured to provide a recommendation regarding further treatment.
24. A kit for monitoring a condition of a biological tissue, the kit
5 comprising:

an implantable device for evaluation of a biological tissue, the device comprising:

a sensor comprising a plurality of electrodes spaced apart from each other;

10 an electric signal source configured to provide an electric signal to one or more pairs of neighboring or non-neighboring electrodes of said plurality of electrodes;

an electric signal measurement unit configured to measure impedance values between each of said one or more pairs of
15 electrodes wherein said signals produced by said electric signal measurement unit are indicative of a characteristic of a biological tissue adjacent the pair of electrodes; and

an anchoring element configured to anchor the implantable device to the biological tissue or to a neighboring tissue; and


20 a biopsy needle.
25. The kit according to claim 24, wherein the implantable device further comprises a wireless transmitter configured to wirelessly transmit said electric signals obtained from said electric signal measurement unit;
26. A method for monitoring a condition of a tumor, the method
25 comprising:

- 5 a) utilizing an impedance sensor implanted in the tumor of a subject, providing an electric signal to one or more pairs of neighboring or non-neighboring electrodes of a plurality of electrodes of the sensor;
- b) measuring, utilizing an electric signal measurement unit, impedance values between each of said one or more pairs of electrodes wherein the signals produced by the electric signal measurement unit are indicative of a characteristic of a biological tissue within or in proximity to the tumor and adjacent the pair of electrodes; and
- 10 c) repeating steps a) and b) after a desired period of time thereby monitoring the condition of the tumor.
27. The method according to claim 26, further comprising utilizing a wireless transmitter, wirelessly transmitting the electric signals obtained from the electric signal measurement unit to processing circuitry outside the subject's body and repeating steps a), b) and c) after a desired period of time.
- 15 28. The method according to claim 26, further comprising implanting the sensor essentially within the tumor.
29. The method according to claim 26, further comprising providing treatment to the subject, wherein the treatment is intended to affect the tumor, and wherein steps a) and b) are performed at least once after the commencement of the treatment.
- 20 30. The method according to claim 26, wherein the desired period of time is in a range of 1 hour to about 7 days.
31. The method according to claim 26, wherein the desired period of time is in a range of about 7-90 days.
- 25 32. The method according to claim 26, wherein said tumor comprises a breast cancer tumor.

33. The method according to claim 26, wherein said tumor is selected from a group consisting of: a solid tumor, a malignant tumor, an adenocarcinoma tumor, an adrenal gland tumor, an ameloblastoma tumor, an anaplastic tumor, an anaplastic carcinoma of the thyroid tumor, an angiofibroma tumor, an angioma tumor, an angiosarcoma tumor, an apudoma tumor, an argentaffinoma tumor, an arrhenoblastoma tumor, an astroblastoma tumor, an astrocytoma tumor, an ataxia-telangiectasia tumor, an atrial myxoma tumor, a basal cell carcinoma tumor, a benign tumor, a bone cancer tumor, a bone tumor, a brainstem glioma tumor, a brain tumor, a breast cancer tumor, a cancerous tumor, a carcinoid tumor, a carcinoma tumor, a cerebellar astrocytoma tumor, a cervical cancer tumor, a cherry angioma tumor, a cholangiocarcinoma tumor, a cholangioma tumor, a chondroblastoma tumor, a chondroma tumor, a chondrosarcoma tumor, a chorioblastoma tumor, a choriocarcinoma tumor, a colon cancer tumor, a craniopharyngioma tumor, a cystocarcinoma tumor, a cystofbroma tumor, a cystoma tumor, a cytoma tumor, a ductal carcinoma in situ tumor, a ductal papilloma tumor, a dysgerminoma tumor, an encephaloma tumor, an endometrial carcinoma tumor, an endothelioma tumor, an ependymoma tumor, an epithelioma tumor, an Ewing's sarcoma tumor, a feline sarcoma tumor, a fibro adenoma tumor, a fibro sarcoma tumor, a follicular cancer of the thyroid tumor, a ganglioglioma tumor, a gastrinoma tumor, aglioblastoma multiform tumor, a glioma tumor, a gonadoblastoma tumor, an haemangioblastoma tumor, an haemangioendothelioblastoma tumor, an haemangioendothelioma tumor, an haemangiopericytoma tumor, an haematolymphangioma tumor, an haemocytoblastoma tumor, an haemocytoma tumor, a hamartoma tumor, an hepatocarcinoma tumor, an hepatocellular carcinoma tumor, an hepatoma tumor, an histoma tumor, an hypernephroma tumor, an infiltrating cancer tumor, an infiltrating ductal carcinoma tumor, an insulinoma tumor, a juvenile angioforoma tumor, a Kaposi sarcoma tumor, a kidney tumor, a lipoma tumor, a liver cancer tumor, a liver metastases tumor, a Lucke carcinoma tumor, a lung cancer tumor, a malignant mesothelioma tumor, a

- malignant teratoma tumor, a mastocytoma tumor, a medulloblastoma tumor, a melanoma tumor, a meningioma tumor, a mesothelioma tumor, a metastatic tumor, a metastasis tumor, a metastatic spread tumor, a Morton's neuroma tumor, a myxoma tumor, a nasopharyngeal carcinoma tumor, a neoplastic tumor, a neuroblastoma tumor, a neuroblastoma tumor, a neurofibroma tumor, a neurofibromatosis tumor, a neuroglioma tumor, a neuroma tumor, an oligodendroglioma tumor, an optic glioma tumor, an osteochondroma tumor, an osteogenic sarcoma tumor, an osteosarcoma tumor, an ovarian cancer tumor, a Paget's disease of the nipple tumor, a pancoast tumor, a pancreatic cancer tumor, a pheochromocytoma tumor, a pheochromocytoma tumor, a primary brain tumor, a progonoma tumor, a prolactinoma tumor, a renal cell carcinoma tumor, a retinoblastoma tumor, a rhabdomyosarcoma tumor, a rhabdosarcoma tumor, sarcoma tumor, a secondary tumor, a seminoma tumor, a skin cancer tumor, a small cell carcinoma tumor, a squamous cell carcinoma tumor, a strawberry haemangioma tumor, a teratoma tumor, a testicular cancer tumor, a thymoma tumor, a trophoblastic tumor, a tumorigenic tumor, a vestibular schwannoma tumor, and a Wilm's tumor.
34. The method according to claim 26, wherein said tumor is selected from a group consisting of: a solid tumor, a malignant tumor, a benign tumor, a brain tumor, a breast cancer tumor, a cancerous tumor, a carcinoid tumor, a carcinoma tumor, a colon cancer tumor, a cystoma tumor, a kidney tumor, a leukemia tumor, a liver cancer tumor, a lung cancer tumor, a melanoma tumor, a metastatic tumor, sarcoma tumor, a secondary tumor, a skin cancer tumor.
35. The method according to claim 26, further comprising augmenting treatment of the tumor using a heating element in or in conjugation with the sensor.
36. The method according to claim 35, wherein heating comprises local heating.

37. The method according to claim 36, wherein local heating comprises elevating the temperature of regions of said biological tissue to a range of 40° C to 90°C.
- 5 38. The method according to claim 35, wherein the treatment augmentation comprises causing necrosis of said tumor.
39. The method according to claim 26, wherein monitoring the condition of the tumor comprises an on-line monitoring.
40. The method according to claim 26, wherein monitoring the condition of the tumor comprises a continuous monitoring.
- 10 41. The method according to claim 26, wherein said monitoring the condition of the tumor comprises monitoring of the effectiveness of a treatment of the tumor.
42. The method according to claim 26, further comprising displaying the at least one characteristic of the tumor in a manner adapted for evaluating the tumor condition by an operator.
- 15 43. The method according to claim 26, further comprising providing indication regarding an effectiveness of a treatment provided to the subject.
44. The method according to claim 27, further comprising providing a recommendation regarding further treatment.
- 20






FIG. 2B




FIG. 2A




FIG. 3




Figure 4

FIG. 4

5/8




FIG. 5

6/8




FIG. 6

7/8




FIG. 7A




FIG. 7B








FIG. 7C

8/8



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2016/050601

A. CLASSIFICATION OF SUBJECT MATTER IPC (2016.01) A61B 5/053, A61B 5/04, A61B 5/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC (2016.01) A61B 5/053 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Databases consulted: Esp@cenet, Google Patents, FamPat database Search terms used: impedance, insert, implant, insert, tumor, tumour, cancer, mass, tissue, sensor, electrode, probe, electric, signal, measure, needle, monitor, treat, diagnose, biochemical		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003199783 A1 BLOOM MATTHEW et al 23 Oct 2003 (2003/10/23) The whole document	1,2,4,9,17,19-21,24
Y	The whole document	3,5-8,10-16,18,22, 23,25-44
Y	US 2013345525 A1 KLINE ERIC V; IBM 26 Dec 2013 (2013/12/26) The whole document	6,11,26,29,41
Y	US US2003009110 A1 TU HOSHENG, QUIJANO RODOLFO C 09 Jan 2003 (2003/01/09) p.3, para.[0031]; p.5, para.[0051]	5,10,35,36
Y	US 2015038872 A1 DARTMOUTH COLLEGE 05 Feb 2015 (2015/02/05) abstract	15,16
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 28 Sep 2016		Date of mailing of the international search report 29 Sep 2016
Name and mailing address of the ISA: Israel Patent Office Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel Facsimile No. 972-2-5651616		Authorized officer ITIN Yulia YuliaI@justice.gov.il Telephone No. 972-2-5651680

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2016/050601

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9833554 A1 MEDTRONIC INC 06 Aug 1998 (1998/08/06) The whole document	1-44
P,X	WO 2015092747 A2 TYLERTON INTERNAT INC; BEN-HAIM SHLOMO; PRUTCHI DAVID; BEN-HAIM YUVAL 25 Jun 2015 (2015/06/25) The whole document	1,17,24

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2016/050601

Patent document cited search report			Publication date	Patent family member(s)			Publication Date
US	2003199783	A1	23 Oct 2003	US	2003199783	A1	23 Oct 2003
				US	6963772	B2	08 Nov 2005
				US	2006047218	A1	02 Mar 2006
US	2013345525	A1	26 Dec 2013	US	2013345525	A1	26 Dec 2013
				US	9320465	B2	26 Apr 2016
				US	2016192839	A1	07 Jul 2016
US	US2003009110	A1	09 Jan 2003	NONE			
US	2015038872	A1	05 Feb 2015	US	2015038872	A1	05 Feb 2015
				US	2016081585	A1	24 Mar 2016
				WO	2015017409	A1	05 Feb 2015
				WO	2015017409	A8	11 Sep 2015
WO	9833554	A1	06 Aug 1998	WO	9833554	A1	06 Aug 1998
				CA	2278292	A1	06 Aug 1998
				CA	2278292	C	16 Dec 2003
				DE	69826012	D1	07 Oct 2004
				DE	69826012	T2	08 Sep 2005
				EP	1011803	A1	28 Jun 2000
				EP	1011803	B1	01 Sep 2004
				US	5957861	A	28 Sep 1999
WO	2015092747	A2	25 Jun 2015	WO	2015092747	A2	25 Jun 2015
				WO	2015092747	A3	17 Sep 2015

专利名称(译)	植入式监控设备		
公开(公告)号	EP3307156A4	公开(公告)日	2018-07-11
申请号	EP2016807030	申请日	2016-06-09
申请(专利权)人(译)	HADASIT医学研究服务和发展有限公司.		
[标]发明人	ROTTENBERG YAKIR		
发明人	ROTTENBERG, YAKIR		
IPC分类号	A61B5/053 A61B5/04 A61B5/00		
CPC分类号	A61B5/0538 A61B5/0022 A61B5/0031 A61B5/0531 A61B5/4836 A61B5/4839 A61B5/4842 A61B5/6848 A61B5/742 A61B10/0233 A61B2560/063 A61B2562/043		
优先权	62/173383 2015-06-10 US		
其他公开文献	EP3307156A1		
外部链接	Espacenet		

摘要(译)

本文提供了一种用于监测生物组织状况的可植入装置，该装置包括：传感器，包括彼此间隔开的多个电极；电信号源，被配置为向一对或多对相邻电子信号提供电信号。或者，所述多个电极的非相邻电极和电信号测量单元，被配置为测量所述一对或多对电极中的每一对之间的阻抗值，其中由所述电信号测量单元产生的所述信号指示生物组织的特征。邻近这对电极。